In another study, Resminostat was found to stimulate mesenchymal HCC cells to have a more epithelial phenotype with lower invasive activity, downregulating CD44 (a cancer stem cell marker) that may contribute to the sensitization to Sorafenib-induced apoptosis, preventing HCC cells growth in vitro [120]. Here, CD44 is linked to hepatocellular carcinoma.